Industry News

Join WhatsApp Channel

- Read more about U.S. District Court Rules in Lilly's Favor on Alimta Vitamin Regimen Patent
Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of Indiana has ruled in the company's favor regarding infringement of the vitamin regimen patent for Alimta® (pemetrexed for injection).
- Read more about Novartis new heart failure medicine got Swiss approval
Novartis announced today that Swissmedic has approved Entresto(TM) (sacubitril/valsartan), previously known as LCZ696, to reduce the risk of cardiovascular mortality and morbidity in patients with heart failure with reduced ejection fraction (HFrEF). Entresto will be available on prescription for adult patients whose condition is classified NYHA class II-IV and with an ejection fraction of 40% or less. It is administered in combination with other heart failure therapies as appropriate, in place of an ACE inhibitor or angiotensin receptor blocker.
- Read more about AstraZeneca purchases US biologics manufacturing facility to support growing pipeline
AstraZeneca purchased high-tech biologics bulk manufacturing facility from Amgen Inc. Over time, the LakeCentre facility, located in Boulder, Colorado will increase manufacturing and production capacity to support the company’s extensive portfolio of biologics medicines.
- Read more about The safety and efficacy of oral, once-daily VRAYLAR was established
U.S. Food and Drug Administration (FDA) has approved VRAYLAR™ (cariprazine) capsules, an atypical antipsychotic, for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for treatment of schizophrenia in adults.

[adsense:336x280:8701650588]
- Read more about Jubilant DraxImage collaborate with Cyclopharm's to market Technegas in US market
Jubilant DraxImage Inc. (DraxImage), a subsidiary of Jubilant Life Sciences and Cyclopharm Limited (CYC), provider of innovative solutions in nuclear medicine signed a term sheet to market and distribute Technegas in the United States. DraxImage will assist CYC with the development and financing of the phase III clinical trials for Technegas, and any other steps required to file for and obtain US FDA approval.
- Read more about Biocon inaugurates world class devices facility & introduces Basalog One™
Biocon Ltd. Asia's premier biopharmaceuticals company, inaugurated a world class facility for manufacturing new generation, patient-friendly devices for its insulins portfolio. The facility was inaugurated by Mr. Amitabh Kant, Secretary, Department of Industrial Promotion and Policy, Govt. of India along with Mr. Kaushik Mukherjee, Chief Secretary, Government of Karnataka and Ms. V. Manjula, Secretary, IT,BT and S&T, Government of Karnataka. Mr Kant also launched Basalog One™, a high-end, ready-to-use insulin glargine disposable pen for better blood sugar management for people with diabetes, manufactured in this facility.
- Read more about Dr. Reddy’s Laboratories signs commercialization deal with Hatchtech
Dr. Reddy’s Laboratories signing of a commercialization deal with Hatchtech, an Australian pharmaceutical company developing an innovative prescription head lice product, Xeglyze™ Lotion. The exclusive rights for this product are applicable for the territories of the United States, Canada, India, Russia and the CIS, Australia, New Zealand and Venezuela.

[adsense:336x280:8701650588]
- Read more about AstraZeneca collaborate with The University of Manchester in new clinical oncology bioinformatics
AstraZeneca, a global, innovation-driven biopharmaceutical business, and The University of Manchester, a member of the prestigious Russell Group of British universities collaborate to deliver personalised healthcare for cancer patients. The five-year agreement will see the organisations apply clinical trial bioinformatics to better identify the right cancer treatment for the right patient at the right time. As part of the collaboration, AstraZeneca will provide a total of £11.5 million.
- Read more about Clinical study confirm the impact of Fenugreek Seed Extract (Furocyst) in Poly Cystic Ovary Syndrome Patients (PCOS)
(Business Wire India); A clinical study conducted on 50 women in the age group of 18-45 years showed significant results in the treatment of polycystic ovary syndrome with the use of Fenugreek seed extract (Furocyst). The average BMI of the study population was 23.88 and had adequate hepatic, renal and haematological functions. At the time of enrolment, most of the patients had prolonged menstrual cycle (81%) and a few had irregular cycle (10%). Rest of the patients (10%) had primary infertilities.

[adsense:336x280:8701650588]
- Read more about In India Bausch & Lomb introduce Obagi’s blockbuster products for transformational skincare
Bausch & Lomb launch Obagi’s blockbuster products like Thermage, Fraxel, Vaser & Clear + Brilliant and few more offerings in the pipeline. This strategic move of expanding in the premium skincare segment, would further strengthen Bausch & Lomb’s position in the INR 285 - 290 billion beauty care market, growing at a rate 15 to 20 per cent per annum (As per FICCI Wellness Report 2013).